Credit Suisse Group set a $151.00 target price on Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report report published on Friday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently weighed in on the stock. Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a buy rating to a conviction-buy rating in a research report on Friday, December 15th. Piper Jaffray Companies reissued a buy rating and set a $182.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 17th. B. Riley reduced their price target on shares of Alnylam Pharmaceuticals to $220.00 and set a buy rating on the stock in a research report on Wednesday, November 8th. Morgan Stanley lifted their price target on shares of Alnylam Pharmaceuticals from $101.00 to $130.00 and gave the stock an equal weight rating in a research report on Thursday, November 9th. Finally, BidaskClub cut shares of Alnylam Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, December 7th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Alnylam Pharmaceuticals has an average rating of Buy and an average price target of $126.98.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) opened at $117.30 on Friday. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14. Alnylam Pharmaceuticals has a fifty-two week low of $44.50 and a fifty-two week high of $147.63. The company has a market cap of $11,530.00, a price-to-earnings ratio of -21.68 and a beta of 2.68.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing analysts’ consensus estimates of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative return on equity of 48.88% and a negative net margin of 545.95%. The business had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. During the same period in the prior year, the firm posted ($1.32) EPS. Alnylam Pharmaceuticals’s revenue was up 116.6% on a year-over-year basis. equities analysts forecast that Alnylam Pharmaceuticals will post -5.69 earnings per share for the current fiscal year.

In related news, CEO John Maraganore sold 74,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $126.86, for a total value of $9,387,640.00. Following the sale, the chief executive officer now directly owns 223,710 shares of the company’s stock, valued at approximately $28,379,850.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Laurie Keating sold 6,249 shares of the business’s stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total transaction of $757,378.80. Following the completion of the sale, the senior vice president now directly owns 17,749 shares in the company, valued at $2,151,178.80. The disclosure for this sale can be found here. Insiders sold a total of 220,409 shares of company stock worth $28,667,017 over the last ninety days. 4.30% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of ALNY. Northern Trust Corp lifted its position in Alnylam Pharmaceuticals by 5.0% during the 2nd quarter. Northern Trust Corp now owns 377,020 shares of the biopharmaceutical company’s stock worth $30,072,000 after buying an additional 17,862 shares in the last quarter. Suntrust Banks Inc. bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth about $320,000. Parametric Portfolio Associates LLC lifted its position in Alnylam Pharmaceuticals by 8.2% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 64,943 shares of the biopharmaceutical company’s stock worth $5,180,000 after buying an additional 4,913 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Alnylam Pharmaceuticals by 59.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 179,429 shares of the biopharmaceutical company’s stock worth $14,311,000 after buying an additional 66,651 shares in the last quarter. Finally, QS Investors LLC lifted its position in Alnylam Pharmaceuticals by 59.7% during the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 900 shares in the last quarter. 88.59% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Alnylam Pharmaceuticals (ALNY) PT Set at $151.00 by Credit Suisse Group” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/02/13/alnylam-pharmaceuticals-alny-pt-set-at-151-00-by-credit-suisse-group.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.